880
Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: a randomized phase III trial.
 ( potential therapeutic event: in ,  patients with multiple myeloma: Subject, Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen: Treatment, multiple myeloma: Treatment.Disorder, bortezomib: Treatment.Drug, lenalidomide/: Treatment.Drug, dexamethasone: Treatment.Drug, bortezomib: Treatment.Drug, dexamethasone: Treatment.Drug, bortezomib: Combination.Drug, lenalidomide/: Combination.Drug, dexamethasone: Combination.Drug, bortezomib: Combination.Drug, dexamethasone: Combination.Drug) 
Locate the role in the text that participated in the event based on the event type and return it in the event list. 
 Option: Event type: adverse event,potential therapeutic event, Arguments type: Treatment.Disorder,Treatment.Time_elapsed,Treatment.Dosage,Subject.Race,Treatment.Drug,Treatment.Route,Subject.Disorder,Treatment.Freq,Treatment,Effect,Subject.Population,Treatment.Duration,Combination.Drug,Subject,Subject.Age,Subject.Gender. 
Text: {0} 
Answer:
 ( potential therapeutic event: in ,  patients with multiple myeloma: Subject, Consolidation therapy with bortezomib/lenalidomide/ dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen: Treatment, multiple myeloma: Treatment.Disorder, bortezomib: Treatment.Drug, lenalidomide/: Treatment.Drug, dexamethasone: Treatment.Drug, bortezomib: Treatment.Drug, dexamethasone: Treatment.Drug, bortezomib: Combination.Drug, lenalidomide/: Combination.Drug, dexamethasone: Combination.Drug, bortezomib: Combination.Drug, dexamethasone: Combination.Drug) 